Lexaria Bioscience - Warrants (11/01/2026) Profit Margin

Lexaria Bioscience - Warrants (11/01/2026)'s profit margin stands at -3985.58% as of May 2026. That compares with -1849.39% in the prior-year period — down 115.5% year over year. That is below the Healthcare sector average of 13.45%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Lexaria Bioscience - Warrants (11/01/2026) reported -3985.58% in profit margin versus -1849.39% a year earlier — a 115.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Lexaria Bioscience - Warrants (11/01/2026) sits lower the Healthcare benchmark (13.45%) with a profit margin of -3985.58%. That is roughly 29737.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -3985.58% for Lexaria Bioscience - Warrants (11/01/2026) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Lexaria Bioscience - Warrants (11/01/2026)'s profit margin evolved across reporting periods, while the comparison chart places LEXXW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.